Reported Earlier, Kodiak Sciences Announced Treatment Of First Patients In Phase 3 GLOW2 Study Of Tarcocimab Tedromer In Diabetic Retinopathy
Reported Earlier, Kodiak Sciences Announced Treatment Of First Patients In Phase 3 GLOW2 Study Of Tarcocimab Tedromer In Diabetic Retinopathy
Kodiak Sciences Inc. (NASDAQ:KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases, announced today that the first patients with diabetic retinopathy (DR) have been treated in the randomized double masked Phase 3 GLOW2 study of tarcocimab tedromer.
致力于研究、开发和商业化治疗广谱视网膜疾病的变革性疗法的生物制药公司柯迪亚克科学公司（纳斯达克股票代码：KOD）今天宣布，在tarcocimab tedromer的随机双面掩盖3期 GLOW2 研究中，首批糖尿病视网膜病变（DR）患者接受了治疗。
GLOW2 is the second Phase 3 study of tarcocimab in diabetic retinopathy in which all patients on investigational therapy will receive tarcocimab on extended dosing intervals, including 6-month dosing for all patients. The GLOW2 study design mirrors the successful GLOW1 study in which tarcocimab-treated patients, over the 48-week study duration, saw 29-fold increased response rate in ≥ 2-step improvement in DRSS (treatment) and 89% decreased risk of developing sight-threatening complications (prevention).
GLOW2 是第二项针对糖尿病视网膜病变的tarcocimab的3期研究，在该研究中，所有接受研究性治疗的患者都将在延长给药间隔内接受tarcocimab，包括所有患者的6个月给药。GLOW2 研究设计反映了成功的 GLOW1 研究，在该研究中，在为期 48 周的研究期间，接受他考西单抗治疗的患者在 DRSS（治疗）的两步改善中反应率提高了 29 倍，出现危及视力的并发症（预防）的风险降低了 89%。
译文内容由第三方软件翻译。